Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent.

Author(s): Arenas R, Fernandez G, Dominguez L

Affiliation(s): Departamento de Dermatologia, Hospital General Dr. Manuel Gea Gonzalez, Mexico.

Publication date & source: 1991-08, Int J Dermatol., 30(8):586-9.

Publication type: Clinical Trial; Randomized Controlled Trial

An open, comparative, randomized study was conducted using griseofulvin or itraconazole for the treatment of onychomycosis of the foot. Group I (45 patients) received itraconazole and Group II (45 patients) received griseofulvin. Each group was divided into three subgroups that received different topical treatment: antimycotic cream (isoconazole 1%), keratolytic cream (urea 40%), or placebo cream. The itraconazole group showed complete clearance in combination with isoconazole cream in 73.3% (11 of 15 patients), in combination with keratolytic cream in 78.5% (11 of 14 patients), and in combination with placebo cream in 91.6% (11 of 12 patients). The griseofulvin group showed complete clearance in combination with isoconazol cream in 46.1% (7 of 15 patients), in combination with keratolytic cream in 42.8% (6 of 15 patients), and in combination with placebo cream in 26.6% (4 of 15 patients). The itraconazole group showed better results compared with the griseofulvin group when the chi-square statistical method was used.